AC Immune SA Stock: price and insider trades · United States

AC Immune SA is a clinical-stage biotechnology company focused on neurodegenerative diseases. It is listed on the NASDAQ market in the United States under the ticker ACIU, while its operational base and corporate headquarters are in Lausanne, Switzerland, at the EPFL Innovation Park. Founded in 2003, the company has built its identity around precision medicine approaches for disorders driven by misfolded proteins, with core focus areas including Alzheimer’s disease, Parkinson’s disease, and selected NeuroOrphan indications. For investors, this is a classic high-risk/high-upside biotech profile: valuation is typically driven by clinical readouts, safety and biomarker data, partnership economics, and balance-sheet visibility.

AC Immune’s business is organized around a differentiated neuroscience pipeline and proprietary technology platforms. The company has developed expertise in targeting key pathological proteins such as tau, alpha-synuclein, amyloid beta, and other misfolded protein species implicated in neurodegeneration. Its portfolio includes active immunotherapies, small-molecule programs, and diagnostic or biomarker-related assets. That combination gives AC Immune exposure to both treatment and early intervention strategies, as well as the possibility of patient stratification through biomarker tools. From an investment standpoint, the company’s scientific platform is important because it can support multiple shots on goal, but the business remains highly dependent on clinical execution.